Thank you very much and welcome again to this Q2 2024 report. Next slide, please. Right. So this is a disclaimer that we will not go through. Next one. All right. Today, we will go through the clearest data available.
Basically, we will review the performance. This will be presented by our CFO, Johnny. Then, I will conclude this call with the near-term milestones of oncology. Right. Shall we have the next slide, please? Right. So, today the speakers, as I mentioned earlier, are myself as the CEO and Johnny, our CFO.
Next slide. Right. So, today is an important call. The reason being that we have fully enrolled our patients in the current CORIST trial. Furthermore, we have achieved the MTD and consequently, we are in the process of finalizing the analysis of the full set of data from our CORIST clinical trial. So that's an important milestone that we, as Scandion Oncology, have achieved over the last few months. And I will come back to that.
With regard to PANTAX, we have released the data actually in H1 of this year. Regarding gastric cancer, we have also released compelling preclinical data, and we are ready to proceed to Phase 1b/2a with regard to our other asset, which is SCO-101. We have decided, mainly due to financial constraints, to pause further development. From a preclinical perspective, these compounds still show potential. It means that we have decided to put the development of this compound on hold. Right. So let's move to the next slide, please.
Right. So, regarding the CORIST Part Three, what have we basically achieved? The last cohort has indeed shown significant tumor reduction, which is defined as more than 30% tumor shrinkage. This was observed in a limited number of patients. Actually, two out of six who have been treated with a four-day schedule using FOLFIRI. We have used the dose of 250mg of SCO-101, and the tumor reduction in a recent study was actually as much less if you look at the percentage. While working with a limited number of patients,
However, the tumor shrinkage that we have observed is significant. We have also observed an exciting clinical benefit rate of 76% after eight weeks. And if you compare it to historical controls, we are talking about a rate of 11 to 16%. Again, this is with a limited number of patients, a limited cohort. However, we believe there is some significance here, encouraging Part Two. We had a clinical benefit rate of about 42%, which was even more significant. We have a promising median overall survival close to eight months and the median progression-free survival around four months. Obviously, we are waiting for further data to mature. This is a classic case in oncology, and we expect to have even better data in a couple of months from now. Also, if we look at historical studies comparing minimum overall survival and median progression-free survival, we are able to show some better data. Another important point is the biomarker. So we've been able to identify UGT1A1 as a potential biomarker, especially with the wild type colorectal cancer patients. And this is certainly an important aspect for future development, because as we know, regulatory bodies now require a biomarker in order to better stratify patients and potentially get an approval, specifically talking about the FDA, but also in Europe. Right. Uh, shall we move to the next slide, please? Well, if we could summarize what we have done over the last few months and even years with regard to queries, we've been able to demonstrate a good safety and tolerability profile for our drug SCO-101. We have been able to show some partial responses in two patients in the last cohort of six patients, with some significant and impressive overall survival ranging between 8 and 10 months. That significant increase in overall survival is even better, is even enhanced if we look at patients expressing wild type UGT1A1, colorectal cancer patients, we are moving up to 13 months. Right. And the last progress that we have been able to show over the last quarter is actually the MTD. So, we've been able to establish an MTD (Maximum Tolerated Dose) for the four day regimen of our compound, SCO-101, combined with FOLFIRI at a 50% dosage and 100% efficacy. So overall, you know, if I look at and could summarize the dataset of queries from 1 to 3, the data is very encouraging. We have an active drug and therefore believe it will be extremely worthwhile to continue the development of this drug.